Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31679014 | 0.93 | CTSL (0.48) | KMT2ASIRT2CTSLHDAC1HDAC2 | |
| SCHEMBL22117407 | 0.87 | SIRT2 (0.50) | SIRT2CTSLFOLH1 | |
| SCHEMBL22117406 | 0.87 | SIRT2 (0.50) | SIRT2CTSLFOLH1 | |
| SCHEMBL31679018 | 0.84 | KMT2A (0.47) | KMT2ASIRT2CTSLHDAC1HDAC2 | |
| SCHEMBL31679031 | 0.83 | DPP8 (0.51) | SIRT2CTSLFOLH1 | |
| SCHEMBL16217863 | 0.83 | KMT2A (0.58) | KMT2APTPN1TPSAB1 | |
| SCHEMBL13495919 | 0.83 | KMT2A (0.61) | KMT2ASIRT2 | |
| SCHEMBL17919592 | 0.83 | KMT2A (0.61) | KMT2ASIRT2 | |
| SCHEMBL178700 | 0.82 | FOLH1 (0.62) | KMT2ASIRT2HDAC1HDAC2FOLH1 | |
| SCHEMBL22804067 | 0.82 | FOLH1 (0.62) | KMT2ASIRT2HDAC1HDAC2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404300-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404300-B2 | Mitochondria-targeting peptides | SSBP1, HSPE1, IMMT | KMT2A 4583/4885SIRT2 1556/4885CTSL 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.